Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. reports recurring financial and operating updates as a life-sciences reagent manufacturer serving therapy, vaccine and molecular-diagnostics workflows. The company organizes revenue around Lab Essentials and Clinical Solutions, with products that include agar plates, microbial culture and cryopreservation media, buffers, molecular biology reagents and water used across research-use and GMP production settings.
Company news commonly covers quarterly and annual results, revenue guidance, segment performance, Clinical Solutions customer activity, cash use, borrowings and free cash flow. Updates also describe Teknova’s modular manufacturing platform and its role in supplying foundational reagents for genomics, synthetic biology, molecular diagnostics and emerging therapeutic modalities.
Teknova (Nasdaq: TKNO) reported second quarter 2026 revenue of $12.2 million, an 18% increase from $10.3 million a year earlier, driven by growth in Lab Essentials and Clinical Solutions. Lab Essentials revenue rose to $9.2 million and Clinical Solutions to $2.4 million, both up 18% year over year.
Gross profit reached $4.9 million with gross margin of 40.1%, up from 38.7%. Operating expenses were $7.8 million, leading to a net loss of $3.2 million, or -$0.06 per share, modestly better than the prior-year loss of $3.6 million. Adjusted EBITDA was -$0.7 million.
Teknova reported total cash and short-term investments of $17.4 million and total borrowings of $13.2 million at June 30, 2026. Free Cash Outflow improved to $0.6 million from $2.3 million. Based on these results, the company raised its 2026 revenue outlook to $45–47 million and now expects Free Cash Outflow of less than $8 million. Teknova also launched Build-Tek™, an AI-powered custom configurator for complex reagent products.
Teknova (Nasdaq: TKNO) launched Build-Tek™, an AI-powered custom order configurator that lets therapeutic and diagnostic developers design complex custom reagents and submit quote requests in minutes. The system, beta-tested since June 2026, now spans Teknova’s full portfolio of products, container formats, and manufacturing grades.
Build-Tek’s interactive assistant guides users through product type, formulation, containers, QC testing, timelines, and add-on services, enabling multiple custom products per session. Teknova’s technical team reviews each request, typically returning a quote in two to three business days, with volumes ranging from 8 to 2,000 liters across RUO, RUO+, and GMP grades.
Alpha Teknova (Nasdaq: TKNO) will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, after the market close. The company will host a webcast and conference call the same day at 6:00 p.m. Eastern Time, accessible via the Investor Relations section of its website, with a replay available about two hours later.
Teknova (Nasdaq: TKNO) reported Q1 2026 revenue of $11.1 million, up 13% year-over-year, driven by Clinical Solutions growth. Gross profit was $3.8 million and gross margin rose to 34.2%. Net loss was $4.6 million (negative $0.08 per diluted share). Adjusted EBITDA improved to negative $2.0 million. Cash and short-term investments were $17.8 million with total borrowings of $13.2 million. The company reaffirmed 2026 revenue guidance of $42–44 million and expects full-year Free Cash Outflow of less than $10 million.
Teknova (Nasdaq: TKNO) will report first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast and conference call the same day beginning at 6:00 p.m. Eastern Time.
Live access and registration details are available via the Investor Relations section of Teknova's website; a replay will be posted about two hours after the event.
Teknova (Nasdaq: TKNO) reported full year 2025 revenue of $40.5M, up 7% year-over-year, and Q4 2025 revenue of $10.0M, up 8% year-over-year. The company provided 2026 revenue guidance of $42–44M and expects Free Cash Outflow of less than $10M for 2026.
Gross margin improved to 33.2% for 2025; Adjusted EBITDA loss narrowed to -$6.7M. Cash and short-term investments were $21.3M with gross debt of $13.2M at year-end.
Teknova (Nasdaq: TKNO) will report fourth-quarter and full-year 2025 financial results on February 26, 2026 after market close.
The company will host a live webcast and conference call on February 26, 2026 at 5:30 p.m. Eastern Time, with a replay available on the investor website about two hours after the event.
Teknova (Nasdaq: TKNO) reported Q3 2025 revenue of $10.5M, a 9% increase versus Q3 2024, marking five consecutive quarters of year‑over‑year revenue growth. Lab Essentials sales rose 16% to $8.3M while Clinical Solutions fell 13% to $1.7M. Gross profit was $3.2M and gross margin improved to 30.7% (versus 0.9% in Q3 2024, adjusted 29.8%). Net loss narrowed to $4.3M (‑$0.08/share). Adjusted EBITDA improved to ‑$1.6M and Free Cash Outflow was $2.4M for the quarter. Cash and short‑term investments were $22.1M with borrowings of $13.2M. The company reaffirmed 2025 revenue guidance of $39–42M and Free Cash Outflow $12M.
Teknova (Nasdaq: TKNO) will report third quarter 2025 financial results for the quarter ended September 30, 2025, on Thursday, November 6, 2025 after market close.
The company will host a webcast and conference call on November 6, 2025, beginning at 5:00 p.m. Eastern Time. Investors can access the live webcast from the Investor Relations section of Teknova's website or by using the provided link, and participants can register to receive a unique PIN and dial-in information. A replay of the webcast will be available on the company website about two hours after the event.
Teknova (Nasdaq: TKNO) reported strong Q2 2025 financial results with total revenue of $10.3 million, marking a 7% increase from Q2 2024. The company achieved four consecutive quarters of year-over-year growth and reaffirmed its 2025 revenue guidance of $39-42 million.
Key financial metrics include: Lab Essentials revenue of $7.8 million (up 2%), Clinical Solutions revenue of $2.1 million (up 32%), and improved gross margin of 38.7% compared to 29.2% in Q2 2024. The company reported a net loss of $3.6 million ($0.07 per share), showing improvement from the $5.4 million loss in Q2 2024. Cash position stands at $24.0 million with total borrowings of $13.2 million.